AU2002351396B2 - Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms - Google Patents

Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms Download PDF

Info

Publication number
AU2002351396B2
AU2002351396B2 AU2002351396A AU2002351396A AU2002351396B2 AU 2002351396 B2 AU2002351396 B2 AU 2002351396B2 AU 2002351396 A AU2002351396 A AU 2002351396A AU 2002351396 A AU2002351396 A AU 2002351396A AU 2002351396 B2 AU2002351396 B2 AU 2002351396B2
Authority
AU
Australia
Prior art keywords
mannitol
sorbitol
composition
present
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002351396A
Other languages
English (en)
Other versions
AU2002351396A1 (en
Inventor
Arun F. Amin
Sarath Chandar
Gary T. Norman
Kalyan S. Nuguru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SPI Pharma Inc
Original Assignee
SPI Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26956682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002351396(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SPI Pharma Inc filed Critical SPI Pharma Inc
Publication of AU2002351396A1 publication Critical patent/AU2002351396A1/en
Application granted granted Critical
Publication of AU2002351396B2 publication Critical patent/AU2002351396B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002351396A 2001-12-17 2002-12-17 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms Expired AU2002351396B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34136601P 2001-12-17 2001-12-17
US60/341,366 2001-12-17
US10/274,227 US7118765B2 (en) 2001-12-17 2002-10-18 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US10/274,227 2002-10-18
PCT/US2002/040506 WO2003051338A1 (en) 2001-12-17 2002-12-17 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms

Publications (2)

Publication Number Publication Date
AU2002351396A1 AU2002351396A1 (en) 2003-06-30
AU2002351396B2 true AU2002351396B2 (en) 2008-09-25

Family

ID=26956682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002351396A Expired AU2002351396B2 (en) 2001-12-17 2002-12-17 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms

Country Status (9)

Country Link
US (4) US7118765B2 (enExample)
EP (1) EP1465604B1 (enExample)
JP (1) JP4472988B2 (enExample)
AU (1) AU2002351396B2 (enExample)
CA (1) CA2470601C (enExample)
ES (1) ES2429529T3 (enExample)
MX (1) MXPA04005955A (enExample)
WO (1) WO2003051338A1 (enExample)
ZA (1) ZA200404998B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348452A1 (en) * 1998-10-27 2000-05-04 Biovail Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20050214365A1 (en) * 2004-03-24 2005-09-29 Gulf Pharmaceutical Industries [Instant dissolving tablet composition for loratidine and desloratidine]
EP1773292B1 (en) * 2004-07-01 2009-03-11 LEK Pharmaceuticals D.D. Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose
WO2006057912A2 (en) * 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
KR20080028361A (ko) * 2005-05-03 2008-03-31 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 퀴닌-함유 제어-방출형 제제
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
US20070287740A1 (en) 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DE202006020168U1 (de) 2005-12-21 2008-07-17 Basf Se Pharmazeutische Formulierung für die Herstellung von schnell zerfallenden Tabletten
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
CA2650498A1 (en) * 2006-03-31 2007-10-11 Rubicon Research Private Limited Orally disintegrating tablets
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
WO2008089773A1 (fr) * 2007-01-22 2008-07-31 Crd Saidal Formulation d'une matrice a desintegration rapide
WO2008089772A1 (fr) * 2007-01-22 2008-07-31 Crd Saidal Formulation d'un comprime orodispersible a base d'acide acetylsalicylique enrobe
US8685457B2 (en) * 2007-06-06 2014-04-01 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
EP2164460B1 (de) 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2164462B1 (de) 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2042160A1 (de) * 2007-09-14 2009-04-01 Basf Se Mittel für die Behandlung von Mund und Rachen in Form von Tabletten
DE102008012295A1 (de) 2008-03-03 2009-09-17 Südzucker AG Mannheim/Ochsenfurt Gemisch zur Herstellung von schnell zerfallenden Tabletten
WO2009124357A1 (en) * 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx
FR2933299B1 (fr) 2008-07-04 2012-02-03 Roquette Freres Mannitol orodispersible
WO2010077878A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
AU2010223105B2 (en) * 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
US20120077888A1 (en) * 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
PT2238974E (pt) 2009-04-09 2013-07-09 E Pharma Trento Spa Granulado para a formulação de comprimidos orodispersíveis
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138670A2 (en) * 2009-05-27 2010-12-02 Mutual Pharmaceutical Company, Inc. Thiocolchicine derivatives, method of making and methods of use thereof
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
WO2011003603A2 (de) * 2009-07-10 2011-01-13 Merck Patent Gmbh Zusammensetzung für die tablettenherstellung und verfahren zu deren herstellung
US20120114717A1 (en) * 2009-07-10 2012-05-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Tableting agent having a low water content, and method for the production thereof
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
US20110178180A1 (en) * 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
WO2011091114A2 (en) 2010-01-22 2011-07-28 Mutual Pharmaceutical Company, Inc. Thiocolchicine and colchicine analogs, methods of making and methods of use thereof
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
US10561621B2 (en) 2010-09-20 2020-02-18 Diane Goll Microencapsulation process and product
AU2012241189A1 (en) * 2010-10-26 2014-04-24 Ix Biopharma Pte Ltd Fast Dissolving Solid Dosage Form
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
JP6521564B2 (ja) 2010-12-22 2019-05-29 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 速崩性の固体被覆剤形
CN103415284B (zh) * 2011-03-09 2016-12-07 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制物
US9265757B2 (en) 2011-08-25 2016-02-23 Aptapharma Inc. Methods of administering antihistamines
BR112014020434B1 (pt) * 2012-02-22 2021-10-13 Fujifilm Toyama Chemical Co., Ltd. Composição farmacêutica sólida
EP3583935A1 (en) 2012-04-25 2019-12-25 SPI Pharma, INC. Crystalline microspheres and the process for manufacturing the same
WO2013171164A1 (en) 2012-05-14 2013-11-21 EJP Pharmaceutical ApS Compositions and formulations for the treatment of halitosis
FI126168B (en) * 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
CN107669649A (zh) * 2012-10-11 2018-02-09 Ix生物制药有限公司 固体剂型
SG11201503275RA (en) 2012-11-22 2015-06-29 Bayer Pharma AG Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US10207004B2 (en) 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
WO2016061486A1 (en) 2014-10-16 2016-04-21 Cargill, Incorporated Process for preparing a directly compressible erythritol & uses thereof
FR3038836B1 (fr) * 2015-07-17 2017-07-14 Roquette Freres Granules de mannitol pour compression directe
EP3135272A1 (en) 2015-08-31 2017-03-01 Basf S.A. Compositions for mouth wash in the form of tablets
EP3419659A1 (en) 2016-02-23 2019-01-02 The Regents of the University of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10064820B2 (en) 2016-09-30 2018-09-04 Aptapharma Inc. Antihistamine compositions, combinations, and use thereof
WO2019143744A1 (en) 2018-01-16 2019-07-25 Applied Materials, Inc. Metal oxide encapsulated drug compositions and methods of preparing the same
US20200022945A1 (en) * 2018-07-18 2020-01-23 Contango Labs Inc. D/B/A Anewsha Rapidly dissolving pharmaceutical compositions and method of manufacturing
KR20220051250A (ko) 2019-08-27 2022-04-26 어플라이드 머티어리얼스, 인코포레이티드 약제 남용 억제 제형들을 위한 증기상 코팅 기술
TW202122111A (zh) 2019-08-27 2021-06-16 美商應用材料股份有限公司 用於藥物溶解度控制之氣相塗層
US11464827B2 (en) 2020-03-10 2022-10-11 Anewsha Holding Group Llc Antiviral pharmaceutical compositions and method of manufacturing
US20240189225A1 (en) * 2020-05-15 2024-06-13 Spi Pharma, Inc. Compositions and methods for hardening
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
WO2023056304A1 (en) 2021-09-30 2023-04-06 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605794A (en) * 1982-12-07 1986-08-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Sorbitol, process for its preparation, and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145146A (en) 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
JPH0830005B2 (ja) 1985-09-25 1996-03-27 ゲルゲリイ、ゲルハルト 崩壊性錠剤とその製造方法
US4990537A (en) 1988-07-11 1991-02-05 Banyu Pharmaceutical Co., Ltd. Anti influenza agent
ATE107854T1 (de) 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd Pharmazeutisches granulat.
US5583215A (en) 1990-06-25 1996-12-10 Towa Chemical Industry Co., Ltd. Crystalline mixture solid containing maltitol and a process for preparing it
IE67345B1 (en) 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
DE4439858A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung
DE19615418A1 (de) * 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
DE19617487A1 (de) 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
US5957471A (en) * 1996-10-28 1999-09-28 Weeks; Bruce V. Snow vehicle
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US6274727B1 (en) 1996-11-15 2001-08-14 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for producing shaped and unshaped polyol masses
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
NZ337749A (en) 1997-05-01 2000-09-29 Nissan Chemical Ind Ltd Benzimidazole derivative and their use in allergy-related disease
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
EP1023049B2 (de) 1997-10-15 2010-10-20 Merck Patent GmbH Herstellung eines direkt verpressbaren tablettierhilfsstoffes
FI107732B (fi) * 1998-03-18 2001-09-28 Xyrofin Oy Laktitolin kiteyttäminen, kiteinen laktitolituote ja sen käyttö
DE19820957A1 (de) 1998-05-11 1999-11-25 Merck Patent Gmbh Verfahren zur Herstellung von Mannit
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US20020071864A1 (en) 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
AU3574500A (en) 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
DE19927537A1 (de) 1999-06-16 2000-12-21 Merck Patent Gmbh Sprühtrocknungsanlage und Verfahren zu ihrer Verwendung
CA2374760A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
AU2001291721A1 (en) 2000-08-25 2002-03-04 Merck Patent G.M.B.H Powdered mannitol and mannitol-containing compositions
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
EP1369109A1 (en) 2001-03-06 2003-12-10 Kyowa Hakko Kogyo Co., Ltd. Preparations quickly disintegrating in oral cavity
WO2002070013A1 (en) 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DE10161402A1 (de) 2001-12-13 2003-06-18 Merck Patent Gmbh Verfahren zur Herstellung von direkt tablettierbarem beta-Mannit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605794A (en) * 1982-12-07 1986-08-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Sorbitol, process for its preparation, and use thereof

Also Published As

Publication number Publication date
CA2470601C (en) 2012-10-02
ES2429529T3 (es) 2013-11-15
EP1465604A4 (en) 2006-11-08
WO2003051338A1 (en) 2003-06-26
EP1465604A1 (en) 2004-10-13
ZA200404998B (en) 2005-07-27
EP1465604B1 (en) 2013-07-17
JP2005520796A (ja) 2005-07-14
US7118765B2 (en) 2006-10-10
US20160051680A1 (en) 2016-02-25
US10702605B2 (en) 2020-07-07
JP4472988B2 (ja) 2010-06-02
US20140023707A1 (en) 2014-01-23
US20060251716A1 (en) 2006-11-09
US9138413B2 (en) 2015-09-22
CA2470601A1 (en) 2003-06-26
US8545889B2 (en) 2013-10-01
US20030118642A1 (en) 2003-06-26
AU2002351396A1 (en) 2003-06-30
HK1067544A1 (en) 2005-04-15
MXPA04005955A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
CA2470601C (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20230255891A1 (en) Highly Compactable and Durable Direct Compression Excipients and Excipient Systems
EP2001450B1 (en) Directly compressible composite for orally disintegrating tablets
EP2560613B1 (en) Fexofenadine-based composition and preparation process therefor
US20110014286A1 (en) Mixture for producing rapidly disintegrating tablets
US11166917B2 (en) Direct injection moldable and rapidly disintegrating tablet matrix
CN103415284A (zh) 用于制备快速崩解的片剂的药物配制物
HK1067544B (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
HK1166024B (en) Highly compactable and durable direct compression excipients and excipient systems

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired